CSNK2A3

Across TCGA pan-cancer cohorts, CSNK2A3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CSNK2A3 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CSNK2A3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSNK2A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

DLBC, PRAD, and SKCM are the cancer types where CSNK2A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
PRAD	OS	Median	All	0.157	0.883	<.001	12	view →
SKCM	DFS	Median	All	0.063	0.757	<.001	9	view →
UCEC	DFS	Median	All	0.957	0.627	.029	6	view →
COAD	DFS	Median	All	0.223	0.696	.017	6	view →
LUSC	OS	Median	All	0.196	0.724	.049	3	view →
STAD	DFS	Median	All	1.000	0.388	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CSNK2A3–DLBC (OS)

Open the DLBC breakdown →